DYN
Dyne Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.23
+6.88%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$14.45
From 52W high−43.13%
Volume3.35M
Market cap$2.84B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$14.45
From 52W high
−43.13%
Volume
3.35M
Market cap
$2.84B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.0x
P/E (TTM)
—
RSI (14)
35.6
MomentumView details →
1D Return
+6.88%
YTD Return
−22.94%
SummaryUpdated Jun 1, 2026
Dyne Therapeutics, Inc. (NASDAQ:DYN) is a clinical-stage biotechnology company founded in 2017 and headquartered in Waltham, Massachusetts. The company went public in September 2020 and focuses exclusively on developing innovative therapeutics for genetically driven muscle diseases. Dyne operates as a specialized muscle disease company, leveraging its proprietary FORCE platform technology to advance potential treatments for rare and devastating muscular conditions that currently have limited or no therapeutic options.
Similar companies
Latest newsMore news →
Dyne Therapeutics announced additional one-year clinical data from the Phase 1/2 ACHIEVE trial of Z-Basivarsen (DYNE-101) for myotonic dystrophy type 1, showing functional improvement versus baseline, placebo, and a matched natural history cohort at 12 months.20d agoShares of Dyne Therapeutics and Sarepta Therapeutics fell on Tuesday after Novartis' muscle disease drug failed a trial, raising investor concerns about similar therapies.41d ago